Description: CKD Bio Corp. manufactures and distributes drug substances based on fermentation, synthesis, and biotechnology in South Korea. It offers drug substances in the areas of antibiotic, ß-lactamase inhibitors, immunosuppressants, anticancer drugs, obesity treatment drugs, dry eye, antivirus, antituberculosis, antihyperlipidemics, and probiotics. The company also provides contract research and development, and manufacturing services for active pharmaceutical ingredients and intermediates, and probiotics. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Home Page: www.ckdbio.com
CKD building
Seoul,
03742
South Korea
Phone:
82 2 2194 0555
Officers
| Name | Title |
|---|---|
| Mr. Jang-Han Lee | Joint Chief Exec. Officer |
| Mr. Hui Yil Kang | Co-Chief Exec. Officer, VP and Director |
| Mr. Tae-Won Kang | Managing Director |
| Mr. Young Tae Kim | Managing Director |
Exchange: KO
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9151 |
| Price-to-Sales TTM: | 0.9185 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 555 |